Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2.

Yan R.

Front Mol Neurosci. 2017 Apr 19;10:97. doi: 10.3389/fnmol.2017.00097. eCollection 2017. Review.

2.

Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.

Yan R, Fan Q, Zhou J, Vassar R.

Neurosci Biobehav Rev. 2016 Jun;65:326-40. doi: 10.1016/j.neubiorev.2016.03.025. Epub 2016 Apr 1. Review.

3.

Application of a Bioinformatics-Based Approach to Identify Novel Putative in vivo BACE1 Substrates.

Johnson JL, Chambers E, Jayasundera K.

Biomed Eng Comput Biol. 2013 Feb 3;5:1-15. doi: 10.4137/BECB.S8383. eCollection 2013.

4.

The normal and pathologic roles of the Alzheimer's β-secretase, BACE1.

Kandalepas PC, Vassar R.

Curr Alzheimer Res. 2014;11(5):441-9. Review.

5.

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

Ghosh AK, Osswald HL.

Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h. Review.

6.

Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.

Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF.

J Neurochem. 2014 Jul;130(1):4-28. doi: 10.1111/jnc.12715. Epub 2014 Apr 19. Review.

7.

Trafficking regulation of proteins in Alzheimer's disease.

Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang YW.

Mol Neurodegener. 2014 Jan 11;9:6. doi: 10.1186/1750-1326-9-6. Review.

8.

Structure-activity relationship of memapsin 2: implications on physiological functions and Alzheimer's disease.

Li X, Hong L, Coughlan K, Wang L, Cao L, Tang J.

Acta Biochim Biophys Sin (Shanghai). 2013 Aug;45(8):613-21. doi: 10.1093/abbs/gmt050. Epub 2013 May 15. Review.

9.

β-Secretase: its biology as a therapeutic target in diseases.

Wang H, Li R, Shen Y.

Trends Pharmacol Sci. 2013 Apr;34(4):215-25. doi: 10.1016/j.tips.2013.01.008. Epub 2013 Feb 27. Review.

10.

Membrane proteases in the bacterial protein secretion and quality control pathway.

Dalbey RE, Wang P, van Dijl JM.

Microbiol Mol Biol Rev. 2012 Jun;76(2):311-30. doi: 10.1128/MMBR.05019-11. Review.

11.

The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond.

Dislich B, Lichtenthaler SF.

Front Physiol. 2012 Feb 17;3:8. doi: 10.3389/fphys.2012.00008. eCollection 2012.

12.

Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.

Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castaño EM, Sabbagh MN, Beach TG, Roher AE.

PLoS One. 2011;6(11):e27291. doi: 10.1371/journal.pone.0027291. Epub 2011 Nov 7.

13.

The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

Lan X, Kiyota T, Hanamsagar R, Huang Y, Andrews S, Peng H, Zheng JC, Swindells S, Carlson GA, Ikezu T.

J Neuroimmune Pharmacol. 2012 Jun;7(2):412-23. doi: 10.1007/s11481-011-9304-5. Epub 2011 Aug 9.

14.

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease.

Vassar R, Kandalepas PC.

Alzheimers Res Ther. 2011 May 31;3(3):20. doi: 10.1186/alzrt82.

15.

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Luo X, Yan R.

Int J Clin Exp Pathol. 2010 Jul 8;3(6):618-28. Review.

16.

Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway.

Lorenzen A, Samosh J, Vandewark K, Anborgh PH, Seah C, Magalhaes AC, Cregan SP, Ferguson SS, Pasternak SH.

Mol Brain. 2010 Apr 21;3:11. doi: 10.1186/1756-6606-3-11.

17.

The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential.

Vassar R, Kovacs DM, Yan R, Wong PC.

J Neurosci. 2009 Oct 14;29(41):12787-94. doi: 10.1523/JNEUROSCI.3657-09.2009. Review.

18.

Mechanism-based treatments for Alzheimer's disease.

Davies P, Koppel J.

Dialogues Clin Neurosci. 2009;11(2):159-69. Review.

19.

The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Cole SL, Vassar R.

Curr Genomics. 2007 Dec;8(8):509-30. doi: 10.2174/138920207783769512.

20.

Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.

O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S, Lichtenthaler SF, Hébert SS, De Strooper B, Haass C, Bennett DA, Vassar R.

Neuron. 2008 Dec 26;60(6):988-1009. doi: 10.1016/j.neuron.2008.10.047.

Supplemental Content

Support Center